Johnson & Johnson advanced its strategy of moving Erleada (apalutamide) into earlier stages of prostate cancer with a supplemental new drug application submission for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) announced on 29 April 2019.
The company is hoping for approval “as soon as possible” thanks to the US Food and Drug Administration’s Real-Time Oncology Review (RTOR) pilot program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?